PBLSNasdaq

Parabilis Medicines, Inc.

Healthcare·Oncology·Phase 1·Cambridge, MA, United States·CEO: Dr. Mathai Mammen M.D., Ph.D.

Oncology

6.0/10

BioSniper Score

2-factor signal

Market Cap

$3.18B

Cash Runway

—

Lead Asset

fog-001 (Phase 1/Phase 2)

Next Catalyst

—

Parabilis Medicines, Inc.: 3 pipeline candidates · 1 clinical trial · Updated within the last hour.

Go deeper on Parabilis Medicines, Inc. with Spotter

Ask follow-up questions and run a full multi-agent deep dive on PBLS — live, with citations.

Ask Spotter

Score breakdown2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity6.0

Lead: Phase 1/Phase 2

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

Key Financials

Cash

Quarterly Burn

Revenue

Pipeline (3 candidates)

Drug	Phase	Indication
fog-001	Phase 1/Phase 2	Cancer
mfolfox-6	Phase 1/Phase 2	Cancer
trifluridine/tipiracil	Phase 1/Phase 2	Cancer

Frequently asked questions

What is Parabilis Medicines, Inc.'s lead drug candidate?

Parabilis Medicines, Inc.'s most advanced tracked candidate is fog-001 (Phase 1/Phase 2) for Cancer.

Who is the CEO of Parabilis Medicines, Inc.?

Dr. Mathai Mammen M.D., Ph.D. is the chief executive officer of Parabilis Medicines, Inc. (PBLS).

Where is Parabilis Medicines, Inc. headquartered?

Parabilis Medicines, Inc. (PBLS) is headquartered in Cambridge, MA, United States.

What therapeutic areas does Parabilis Medicines, Inc. focus on?

Parabilis Medicines, Inc. develops therapies across Oncology.

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.

Get the full picture on Parabilis Medicines, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free Analysis Browse Calendar